Troy Lister is Chief Scientific Officer at Verve Therapeutics, Inc. (VERV). They have made 1 open-market trade across 1 company since 2025, most recently 2025-07-25.
CIK 0002023489
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VERV | 6,952 | $77K |
Shares reported on the most recent Form 4, priced at the 2025-04-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERV | SELL | 2025-04-02 | 2025-04-03 | $4.15 | $9K | +34.3% | +39.5% | +203.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.